Geoff Chong

Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study

Arvind Dasari, Sara Lonardi, Rocio García‐Carbonero et al. · The Lancet · 2023 · 279 citations · Full text

Oncology, Gastrointestinal Oncology, Colorectal Cancer +6

Mucinous histology predicts for reduced fluorouracil responsiveness and survival in advanced colorectal cancer

Francesca Negri, A. Wotherspoon, David Cunningham et al. · Annals of Oncology · 2005 · 160 citations

Gastrointestinal Oncology, Reduced Fluorouracil Responsiveness, Medicine +8

Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan

Geoff Chong, J. Dickson, David Cunningham et al. · British Journal of Cancer · 2005 · 65 citations · Full text

Clinical, Pharmacodynamic, and Pharmacokinetic Evaluation of BNC105P: A Phase I Trial of a Novel Vascular Disrupting Agent and Inhibitor of Cancer Cell Proliferation

Danny Rischin, David C. Bibby, Geoff Chong et al. · Clinical Cancer Research · 2011 · 62 citations

Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14

Mark Hertzberg, Maher K. Gandhi, Judith Trotman et al. · Haematologica · 2016 · 55 citations · Full text